GB0202015D0 - Piperazine Derivatives - Google Patents

Piperazine Derivatives

Info

Publication number
GB0202015D0
GB0202015D0 GBGB0202015.4A GB0202015A GB0202015D0 GB 0202015 D0 GB0202015 D0 GB 0202015D0 GB 0202015 A GB0202015 A GB 0202015A GB 0202015 D0 GB0202015 D0 GB 0202015D0
Authority
GB
United Kingdom
Prior art keywords
piperazine derivatives
piperazine
derivatives
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Ceased
Application number
GBGB0202015.4A
Other languages
English (en)
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
F Hoffmann La Roche AG
Ligand UK Research Ltd
Original Assignee
F Hoffmann La Roche AG
Vernalis Research Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by F Hoffmann La Roche AG, Vernalis Research Ltd filed Critical F Hoffmann La Roche AG
Priority to GBGB0202015.4A priority Critical patent/GB0202015D0/en
Publication of GB0202015D0 publication Critical patent/GB0202015D0/en
Priority to DK03702462T priority patent/DK1472255T3/da
Priority to PCT/EP2003/000459 priority patent/WO2003064423A1/en
Priority to EA200400881A priority patent/EA200400881A1/ru
Priority to IL16272703A priority patent/IL162727A0/xx
Priority to AU2003205622A priority patent/AU2003205622B2/en
Priority to MXPA04007147A priority patent/MXPA04007147A/es
Priority to KR1020047011619A priority patent/KR100644004B1/ko
Priority to DE60303791T priority patent/DE60303791T2/de
Priority to YU65704A priority patent/RS65704A/sr
Priority to BR0307291-6A priority patent/BR0307291A/pt
Priority to JP2003564046A priority patent/JP4213042B2/ja
Priority to PL03371922A priority patent/PL371922A1/xx
Priority to PT03702462T priority patent/PT1472255E/pt
Priority to CNB03802943XA priority patent/CN1290847C/zh
Priority to SI200330231T priority patent/SI1472255T1/sl
Priority to EP03702462A priority patent/EP1472255B1/en
Priority to AT03702462T priority patent/ATE318817T1/de
Priority to HR20040653A priority patent/HRP20040653A2/hr
Priority to ES03702462T priority patent/ES2259757T3/es
Priority to CA002472954A priority patent/CA2472954C/en
Priority to US10/350,616 priority patent/US7098337B2/en
Priority to PE2003000073A priority patent/PE20030847A1/es
Priority to ARP030100229A priority patent/AR038237A1/es
Priority to GT200300015A priority patent/GT200300015A/es
Priority to UY27627A priority patent/UY27627A1/es
Priority to TW092101825A priority patent/TW200307683A/zh
Priority to PA20038564001A priority patent/PA8564001A1/es
Priority to MA27756A priority patent/MA27097A1/fr
Priority to ZA200405458A priority patent/ZA200405458B/en
Priority to TNP2004000136A priority patent/TNSN04136A1/en
Priority to EC2004005208A priority patent/ECSP045208A/es
Priority to NO20043547A priority patent/NO20043547L/no
Ceased legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
    • C07D471/12—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains three hetero rings
    • C07D471/14—Ortho-condensed systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A61P15/10—Drugs for genital or sexual disorders; Contraceptives for impotence
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/02—Drugs for dermatological disorders for treating wounds, ulcers, burns, scars, keloids, or the like
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/06—Antimigraine agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/08—Antiepileptics; Anticonvulsants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A61P25/16—Anti-Parkinson drugs
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/18—Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/20—Hypnotics; Sedatives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/22—Anxiolytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/24—Antidepressants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
    • A61P25/32—Alcohol-abuse
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/04—Anorexiants; Antiobesity agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/12—Antidiuretics, e.g. drugs for diabetes insipidus
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
    • C07D487/12—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains three hetero rings
    • C07D487/14—Ortho-condensed systems

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Biomedical Technology (AREA)
  • Neurosurgery (AREA)
  • Neurology (AREA)
  • Diabetes (AREA)
  • Psychiatry (AREA)
  • Hematology (AREA)
  • Pain & Pain Management (AREA)
  • Endocrinology (AREA)
  • Addiction (AREA)
  • Obesity (AREA)
  • Reproductive Health (AREA)
  • Psychology (AREA)
  • Gynecology & Obstetrics (AREA)
  • Dermatology (AREA)
  • Hospice & Palliative Care (AREA)
  • Child & Adolescent Psychology (AREA)
  • Anesthesiology (AREA)
  • Cardiology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Emergency Medicine (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Epoxy Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Photoreceptors In Electrophotography (AREA)
GBGB0202015.4A 2002-01-29 2002-01-29 Piperazine Derivatives Ceased GB0202015D0 (en)

Priority Applications (33)

Application Number Priority Date Filing Date Title
GBGB0202015.4A GB0202015D0 (en) 2002-01-29 2002-01-29 Piperazine Derivatives
CA002472954A CA2472954C (en) 2002-01-29 2003-01-17 Aza-arylpiperazines
EP03702462A EP1472255B1 (en) 2002-01-29 2003-01-17 Aza-arylpiperazines
AT03702462T ATE318817T1 (de) 2002-01-29 2003-01-17 Aza-arylpiperazine
EA200400881A EA200400881A1 (ru) 2002-01-29 2003-01-17 Азаарилпиперазины
IL16272703A IL162727A0 (en) 2002-01-29 2003-01-17 Aza-arylpiperazines
AU2003205622A AU2003205622B2 (en) 2002-01-29 2003-01-17 Aza-arylpiperazines
MXPA04007147A MXPA04007147A (es) 2002-01-29 2003-01-17 Aza-arilpiperazinas.
KR1020047011619A KR100644004B1 (ko) 2002-01-29 2003-01-17 아자-아릴피페라진
DE60303791T DE60303791T2 (de) 2002-01-29 2003-01-17 Aza-arylpiperazine
YU65704A RS65704A (sr) 2002-01-29 2003-01-17 Aza-arilpiperazini
BR0307291-6A BR0307291A (pt) 2002-01-29 2003-01-17 Composto; processo para a preparação de um composto; composição farmacêutica; uso de um composto; método para o tratamento e profilaxia de distúrbios diversos e de obesidade em um humano
JP2003564046A JP4213042B2 (ja) 2002-01-29 2003-01-17 アザ−アリールピペラジン
PL03371922A PL371922A1 (en) 2002-01-29 2003-01-17 Aza-arylpiperazines
PT03702462T PT1472255E (pt) 2002-01-29 2003-01-17 Aza-arilpiperazinas
CNB03802943XA CN1290847C (zh) 2002-01-29 2003-01-17 氮杂－芳基哌嗪类化合物
SI200330231T SI1472255T1 (sl) 2002-01-29 2003-01-17 Aza-arilpiperazini
DK03702462T DK1472255T3 (da) 2002-01-29 2003-01-17 Aza-arylpiperaziner
ES03702462T ES2259757T3 (es) 2002-01-29 2003-01-17 Aza-arilpiperazinas.
PCT/EP2003/000459 WO2003064423A1 (en) 2002-01-29 2003-01-17 Aza-arylpiperazines
HR20040653A HRP20040653A2 (hr) 2002-01-29 2003-01-17 Aza-arylpiperazines
US10/350,616 US7098337B2 (en) 2002-01-29 2003-01-24 1,2,3,4,9,9a-hexahydro-2,4a,5-triaza-fluorene and 1,2,3,4-tetrahydro-2,4a,5-triaza-fluorene derivatives
PE2003000073A PE20030847A1 (es) 2002-01-29 2003-01-24 Aza-arilpiperazinas como ligandos del receptor 5ht2
ARP030100229A AR038237A1 (es) 2002-01-29 2003-01-27 Aza-arilpiperazinas
GT200300015A GT200300015A (es) 2002-01-29 2003-01-27 Aza-arilpiperazinas
UY27627A UY27627A1 (es) 2002-01-29 2003-01-28 Aza - arilpiperazinas
TW092101825A TW200307683A (en) 2002-01-29 2003-01-28 Aza-arylpiperazines
PA20038564001A PA8564001A1 (es) 2002-01-29 2003-01-28 Aza-arilpiperazinas
MA27756A MA27097A1 (fr) 2002-01-29 2004-06-30 Aza-arylpiperazines
ZA200405458A ZA200405458B (en) 2002-01-29 2004-07-08 Aza-arylpiperazines.
TNP2004000136A TNSN04136A1 (en) 2002-01-29 2004-07-22 Aza-arylpiperazines
EC2004005208A ECSP045208A (es) 2002-01-29 2004-07-27 Aza-arilpiperazinas
NO20043547A NO20043547L (no) 2002-01-29 2004-08-25 Aza-arylpiperaziner

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
GBGB0202015.4A GB0202015D0 (en) 2002-01-29 2002-01-29 Piperazine Derivatives

Publications (1)

Publication Number Publication Date
GB0202015D0 true GB0202015D0 (en) 2002-03-13

Family

ID=9929954

Family Applications (1)

Application Number Title Priority Date Filing Date
GBGB0202015.4A Ceased GB0202015D0 (en) 2002-01-29 2002-01-29 Piperazine Derivatives

Country Status (33)

Country Link
US (1) US7098337B2 (enExample)
EP (1) EP1472255B1 (enExample)
JP (1) JP4213042B2 (enExample)
KR (1) KR100644004B1 (enExample)
CN (1) CN1290847C (enExample)
AR (1) AR038237A1 (enExample)
AT (1) ATE318817T1 (enExample)
AU (1) AU2003205622B2 (enExample)
BR (1) BR0307291A (enExample)
CA (1) CA2472954C (enExample)
DE (1) DE60303791T2 (enExample)
DK (1) DK1472255T3 (enExample)
EA (1) EA200400881A1 (enExample)
EC (1) ECSP045208A (enExample)
ES (1) ES2259757T3 (enExample)
GB (1) GB0202015D0 (enExample)
GT (1) GT200300015A (enExample)
HR (1) HRP20040653A2 (enExample)
IL (1) IL162727A0 (enExample)
MA (1) MA27097A1 (enExample)
MX (1) MXPA04007147A (enExample)
NO (1) NO20043547L (enExample)
PA (1) PA8564001A1 (enExample)
PE (1) PE20030847A1 (enExample)
PL (1) PL371922A1 (enExample)
PT (1) PT1472255E (enExample)
RS (1) RS65704A (enExample)
SI (1) SI1472255T1 (enExample)
TN (1) TNSN04136A1 (enExample)
TW (1) TW200307683A (enExample)
UY (1) UY27627A1 (enExample)
WO (1) WO2003064423A1 (enExample)
ZA (1) ZA200405458B (enExample)

Families Citing this family (34)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7405210B2 (en) 2003-05-21 2008-07-29 Osi Pharmaceuticals, Inc. Pyrrolopyridine-2-carboxylic acid amide inhibitors of glycogen phosphorylase
NZ543482A (en) * 2003-05-21 2009-02-28 Prosidion Ltd Pyrrolopyridine-2-carboxylic acid amide inhibitors of glycogen phoshorylase
GB0314967D0 (en) * 2003-06-26 2003-07-30 Hoffmann La Roche Piperazine derivatives
TW200528102A (en) * 2003-10-24 2005-09-01 Solvay Pharm Gmbh Novel medical combination treatment of obesity involving 4,5-dihydro-1h-pyrazole derivatives having cb1-antagonistic activity
RU2006117637A (ru) * 2003-10-24 2007-12-10 Зольвай Фармасьютиклз Гмбх (De) Комбинированное лечение ожирения с применением избирательных антагонистов cb1-рецептора и ингибиторов липаз
EP1792629A4 (en) 2004-08-25 2010-08-25 Takeda Pharmaceutical MEANS FOR THE PREVENTION / TREATMENT OF STRESS-RELATED HARNINE INCONTINENCE AND PRECAUTIONARY METHOD FOR THIS
AU2005298692A1 (en) 2004-10-25 2006-05-04 Solvay Pharmaceuticals Gmbh Pharmaceutical compositions comprising CB1 cannabinoid receptor antagonists and potassium channel openers for the treatment of diabetes mellitus type I, obesity and related conditions
EP1888585B1 (en) * 2005-05-03 2011-06-29 F. Hoffmann-La Roche AG Tetracyclic azapyrazinoindolines as 5-ht2 ligands
WO2006125179A1 (en) * 2005-05-19 2006-11-23 Xenon Pharmaceuticals Inc. Tricyclic compounds and their uses as therapeutic agents
EP1966199B1 (en) * 2005-11-18 2010-10-20 F. Hoffmann-La Roche AG Azaindole-2-carboxamide derivatives
CN101321761A (zh) * 2005-12-09 2008-12-10 霍夫曼-拉罗奇有限公司 用于治疗肥胖病的三环酰胺衍生物
DE602006014305D1 (de) 2005-12-16 2010-06-24 Hoffmann La Roche Pyrroloä2,3-büpyridinderivate als modulatoren des h3-rezeptors
JP5528699B2 (ja) 2006-05-16 2014-06-25 武田薬品工業株式会社 縮合複素環化合物およびその用途
EP2061767B1 (de) 2006-08-08 2014-12-17 Sanofi Arylaminoaryl-alkyl-substituierte Imidazolidin-2,4-dione, Verfahren zu ihrer Herstellung, diese Verbindungen enthaltende Arzneimittel und ihre Verwendung
WO2009063992A1 (ja) 2007-11-15 2009-05-22 Takeda Pharmaceutical Company Limited 縮合ピリジン誘導体およびその用途
US8470841B2 (en) 2008-07-09 2013-06-25 Sanofi Heterocyclic compounds, processes for their preparation, medicaments comprising these compounds, and the use thereof
WO2010068601A1 (en) 2008-12-08 2010-06-17 Sanofi-Aventis A crystalline heteroaromatic fluoroglycoside hydrate, processes for making, methods of use and pharmaceutical compositions thereof
CN102482312A (zh) 2009-08-26 2012-05-30 赛诺菲 新颖的杂芳族氟代糖苷结晶水合物、含有这些化合物的药物和它们的用途
EP2510949A4 (en) 2009-12-11 2013-11-13 Astellas Pharma Inc THERAPEUTICS FOR FIBROMYALGIA
FR2960876B1 (fr) 2010-06-03 2012-07-27 Sanofi Aventis Derives de 3,4-dihydropyrrolo[1,2-a]pyrazine-2,8(1h)-dicarboxamide leur preparation et leur application en therapeutique.
US8846666B2 (en) 2011-03-08 2014-09-30 Sanofi Oxathiazine derivatives which are substituted with benzyl or heteromethylene groups, method for producing them, their use as medicine and drug containing said derivatives and the use thereof
WO2012120051A1 (de) 2011-03-08 2012-09-13 Sanofi Mit adamantan- oder noradamantan substituierte benzyl-oxathiazinderivate, diese verbindungen enthaltende arzneimittel und deren verwendung
EP2683705B1 (de) 2011-03-08 2015-04-22 Sanofi Di- und trisubstituierte oxathiazinderivate, verfahren zu deren herstellung, ihre verwendung als medikament sowie sie enthaltendes arzneimittel und deren verwendung
EP2683699B1 (de) 2011-03-08 2015-06-24 Sanofi Di- und trisubstituierte oxathiazinderivate, verfahren zu deren herstellung, ihre verwendung als medikament sowie sie enthaltendes arzneimittel und deren verwendung
WO2012120053A1 (de) 2011-03-08 2012-09-13 Sanofi Verzweigte oxathiazinderivate, verfahren zu deren herstellung, ihre verwendung als medikament sowie sie enthaltendes arzneimittel und deren verwendung
EP2683703B1 (de) 2011-03-08 2015-05-27 Sanofi Neue substituierte phenyl-oxathiazinderivate, verfahren zu deren herstellung, diese verbindungen enthaltende arzneimittel und deren verwendung
EP2683702B1 (de) 2011-03-08 2014-12-24 Sanofi Neue substituierte phenyl-oxathiazinderivate, verfahren zu deren herstellung, diese verbindungen enthaltende arzneimittel und deren verwendung
US8901114B2 (en) 2011-03-08 2014-12-02 Sanofi Oxathiazine derivatives substituted with carbocycles or heterocycles, method for producing same, drugs containing said compounds, and use thereof
WO2012120056A1 (de) 2011-03-08 2012-09-13 Sanofi Tetrasubstituierte oxathiazinderivate, verfahren zu deren herstellung, ihre verwendung als medikament sowie sie enthaltendes arzneimittel und deren verwendung
US10202392B2 (en) * 2012-04-26 2019-02-12 Francis Xavier Tavares Synthesis of lactams
AR092041A1 (es) * 2012-08-06 2015-03-18 Hoffmann La Roche Piperazino[1,2-a]indol-1-onas y [1,4]diazepino[1,2-a]indol-1-ona
WO2015066344A1 (en) 2013-11-01 2015-05-07 Arena Pharmaceuticals, Inc. 5-ht2c receptor agonists and compositions and methods of use
EA038219B1 (ru) * 2016-08-19 2021-07-26 Арена Фармасьютикалз, Инк. Агонисты рецептора 5-ht2c и композиции, а также способ их применения
EP3733204A4 (en) 2017-12-27 2021-09-15 Takeda Pharmaceutical Company Limited THERAPEUTIC AGENT FOR URINARY INCONTINENCE OF STRESS AND FECAL INCONTINENCE

Family Cites Families (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA1247547A (en) 1983-06-22 1988-12-28 Paul Hadvary Leucine derivatives
CA1270837A (en) 1984-12-21 1990-06-26 Hoffmann-La Roche Limited Oxetanones
CA1328881C (en) 1984-12-21 1994-04-26 Pierre Barbier Process for the manufacture of oxetanones
CA2035972C (en) 1990-02-23 2006-07-11 Martin Karpf Process for the preparation of oxetanones
US5274143A (en) 1991-07-23 1993-12-28 Hoffmann-La Roche Inc. Process for the preparation of (R)-3-hexyl-5,6-dihydro-4-hydroxy-6-undecyl-2H-pyran-2-one and (R)-5,6-dihydro-6-undecyl-2H-pyran-2,4(3H)-dione
US6004996A (en) 1997-02-05 1999-12-21 Hoffman-La Roche Inc. Tetrahydrolipstatin containing compositions
US6267952B1 (en) 1998-01-09 2001-07-31 Geltex Pharmaceuticals, Inc. Lipase inhibiting polymers
TR200100471T2 (tr) 1998-08-14 2001-07-23 F.Hoffmann-La Roche Ag Lipaz inhibitörleri içeren farmasötik bileşimler
AU759388B2 (en) 1998-08-14 2003-04-10 Cheplapharm Arzneimittel Gmbh Pharmaceutical compositions containing lipase inhibitors and chitosan
GB9902047D0 (en) * 1999-01-29 1999-03-17 Cerebrus Ltd Chemical compounds XI
FR2799757B1 (fr) * 1999-10-15 2001-12-14 Adir Nouveaux derives polycycliques azaindoliques, leur procede de preparation et les compositions pharmaceutiques qui les contiennent

Also Published As

Publication number Publication date
PE20030847A1 (es) 2003-10-21
ECSP045208A (es) 2004-09-28
RS65704A (sr) 2006-10-27
DK1472255T3 (da) 2006-07-10
UY27627A1 (es) 2003-07-31
JP4213042B2 (ja) 2009-01-21
MA27097A1 (fr) 2004-12-20
ATE318817T1 (de) 2006-03-15
AR038237A1 (es) 2005-01-05
WO2003064423A1 (en) 2003-08-07
SI1472255T1 (sl) 2006-06-30
AU2003205622B2 (en) 2006-10-19
ZA200405458B (en) 2006-02-22
IL162727A0 (en) 2005-11-20
TW200307683A (en) 2003-12-16
CA2472954C (en) 2009-04-28
PT1472255E (pt) 2006-06-30
KR20040077885A (ko) 2004-09-07
CA2472954A1 (en) 2003-08-07
EA200400881A1 (ru) 2005-02-24
DE60303791D1 (en) 2006-04-27
PA8564001A1 (es) 2003-09-05
GT200300015A (es) 2003-09-12
KR100644004B1 (ko) 2006-11-10
ES2259757T3 (es) 2006-10-16
CN1290847C (zh) 2006-12-20
BR0307291A (pt) 2004-12-07
TNSN04136A1 (en) 2007-03-12
DE60303791T2 (de) 2006-11-02
JP2005521671A (ja) 2005-07-21
US20030207888A1 (en) 2003-11-06
NO20043547L (no) 2004-08-25
US7098337B2 (en) 2006-08-29
PL371922A1 (en) 2005-07-11
CN1625558A (zh) 2005-06-08
HRP20040653A2 (hr) 2005-06-30
MXPA04007147A (es) 2004-10-29
EP1472255B1 (en) 2006-03-01
EP1472255A1 (en) 2004-11-03

Similar Documents

Publication Publication Date Title
GB0202015D0 (en) Piperazine Derivatives
AP1850A (en) Spiroindolineplperidine derivatives
EG24050A (en) Heterocylocarboxamide derivatives
PL374718A1 (en) Azolidinone-vinyl fused-benzene derivatives
IL166121A0 (en) Indole-3-sulphur derivatives
EP1522540A4 (en) AZAARENE DERIVATIVES
PL376475A1 (en) N-substituted-2-oxodihydropyridine derivatives
PL375220A1 (en) Piperidine derivatives
PL369076A1 (en) Piperazine derivative
TWI368482B (en) New 2-pyridinylethylbenzamide derivatives
GB0315870D0 (en) Heterocyclic derivatives
IL166426A0 (en) N-biarylmethyl aminocycloalkanecarboxamide derivatives
IL162765A0 (en) Piperidine derivatives
GB0106177D0 (en) Piperazine derivatives
AU2003222659A8 (en) 23-o-substituted 5-o-mycaminosyltylonide derivatives
EP1531854A4 (en) O-DERIVATED NOCATHIACIN DERIVATIVES
GB0219687D0 (en) Benzyl morpholine derivatives
GB0213488D0 (en) 2-Naphthamide derivatives
GB0326148D0 (en) Morpholine derivatives
AU2003243397A8 (en) Homo-camptothecin derivatives
GB0220962D0 (en) Heterocyclic derivatives
AP2005003311A0 (en) Substituted aralkyl derivatives
GB0311957D0 (en) Heterocyclic derivatives
GB0219894D0 (en) Dihydropyridinone derivatives
AU2003285777A8 (en) 3-substituted-4-pyrimidone derivatives

Legal Events

Date Code Title Description
AT Applications terminated before publication under section 16(1)